Administration of NF-κB inhibitors to the cancer cells via NPs that are capable of directly inhibiting NF-κB activation by the proteasomal degradation of NF-κB seems an important strategy for the treatment of breast cancers in which NF-κB is over-activated. Here, NFKB1 is linked to breast carcinoma.